Promising prostate cancer trial for hispanic and black patients pulled before start

NCT ID NCT06392841

Terminated Disease control Sponsor: Qian Qin Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 27 times

Summary

This was a phase 2 trial testing a combination of niraparib and abiraterone plus prednisone for metastatic hormone-sensitive prostate cancer in Hispanic/Latino and Black patients with specific gene mutations. The study aimed to enroll 64 people but was withdrawn before any participants were recruited. No results are available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Niraparib and abiraterone acetate plus prednisone

What this could lead to

If successful, this could point toward a more effective treatment option for metastatic prostate cancer in Hispanic/Latino and Black patients with specific genetic mutations.

What could go wrong

The trial was withdrawn before enrolling any participants, so no data is available. It is unclear if the combination therapy would be safe or effective in this population.

Conditions

The condition(s) this trial relates to.

BRCA2-related cancer predisposition CHEK2-related cancer predisposition metastatic prostate carcinoma PALB2-related cancer predisposition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 GENE MUTATION BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CHEK2 GENE MUTATION DELETERIOUS HRR GENE MUTATION FANCA GENE MUTATION METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) PALB2 GENE MUTATION RAD51B GENE MUTATION RAD51B GENE MUTATION RAD51B GENE MUTATION RAD54L GENE MUTATION RAD54L GENE MUTATION